Sandoz launches generic Fusilev

PRINCETON, N.J. — Sandoz on Friday announced the launch of levoleucovorin injection ready-to-use single use vial, a generic version of Fusilev, which is marketed by Spectrum Pharmaceuticals. 

According to Sandoz, the drug is indicated for “rescue use after high-dose methotrexate therapy in bone cancer; diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent over dosage of folic acid antagonists.”

"Sandoz is pleased to expand our high-quality portfolio of oncology injectables with this product launch,” said Peter Goldschmidt, president of Sandoz. “Generics, which offer the same quality and efficacy as branded pharmaceuticals, play an important role in increasing access while providing significant cost savings to payers, patients and healthcare systems.”

U.S. sales for levoleucovorin totaled $185 million for the 12 months ending February 2015, according to IMS Health data.